ImPact Biotech to Present Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at Upcoming Medical Conferences
April 24, 2024 10:00 ET
|
ImPact Biotech
Preliminary results from Phase 3 ENLIGHTED study in low grade upper tract urothelial cancer (UTUC) to be presented at AUA and ASCO Trial design for Phase 1 study of Padeliporfin VTP in pancreatic...
ImPact Biotech Receives FDA Clearance of IND Application for Padeliporfin VTP in Pancreatic Cancer
December 20, 2023 08:00 ET
|
ImPact Biotech
Phase 1 clinical trial expected to initiate in 1H 2024 –IND clearance in third indication reflects broad platform potential for Padeliporfin VTP across a range of solid tumors – TEL AVIV, Israel,...
ImPact Biotech Announces Appointment of Eyal Morag, M.D. as Chief Medical Officer
December 18, 2023 14:53 ET
|
ImPact Biotech
TEL AVIV, Israel, Dec. 18, 2023 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin Vascular Targeted Photodynamic (VTP) therapy to treat a...
ImPact Biotech Announces Research Collaboration to develop a treatment to arrest Pathologic Myopia using its Padeliporfin minimally invasive platform
August 13, 2023 16:16 ET
|
ImPact Biotech
ImPact Biotech to collaborate with Maastricht University researchers to develop a treatment to arrest the progressive condition Pathologic Myopia, a leading cause of irreversible sight impairment and...
ImPact Biotech receives FDA Clearance for Padeliporfin VTP Phase 1 Clinical Program in Peripheral Lung Cancer
August 04, 2023 10:49 ET
|
ImPact Biotech
Padeliporfin VTP Phase 1 trial in Peripheral Non-Small Cell Lung Cancer to start by end Q4 2023 TEL AVIV, Israel, Aug. 04, 2023 (GLOBE NEWSWIRE) -- ImPact Biotech,...
ImPact Biotech receives FDA Orphan Drug Designation for Padeliporfin VTP in Pancreatic Cancer
July 05, 2023 09:44 ET
|
ImPact Biotech
Designation confers advantages including marketing exclusivity and tax credits Padeliporfin VTP Phase 1 trial in Pancreatic cancer to start by end Q4 2023 TEL AVIV, Israel, July 05, 2023 (GLOBE...